Gene
AURKA
AURKA is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (27), Actionable biomarkers (2), Trial mentions (27), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention AURKA. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 6 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 5 of 8,875 | 0.06% | not measured | |
| 2024 | 6 of 8,597 | 0.07% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 21 of 11,460 | 0.18% |
| 2022 | 2 of 8,285 | 0.02% | 14 of 13,598 | 0.10% |
| 2021 | 1 of 8,692 | 0.01% | 27 of 15,045 | 0.18% |
| 2020 | 1 of 7,640 | 0.01% | 22 of 14,459 | 0.15% |
| 2019 | 1 of 7,300 | 0.01% | 20 of 12,159 | 0.16% |
| 2018 | 1 of 6,927 | 0.01% | 12 of 11,854 | 0.10% |
| 2017 | 1 of 6,558 | 0.02% | 12 of 11,595 | 0.10% |
Showing 10 of 37 years.
Assay-provider ledger (27)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Analytical validation | 1 | September 01, 2021 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 3 | May 17, 2021 |
| Affymetrix | Reagent supplier | Clinical validation | 1 | November 01, 2020 |
| NanoString Technologies | Unclassified | Clinical validation | 1 | November 01, 2020 |
| AB Applied Biosystems | Reagent supplier | Clinical validationAnalytical validation | 1 | April 24, 2020 |
Showing 5 of 27 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| AURKA amplification | Aurk Inhibitors | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
| AURKA amplification | Aurk Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (27)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07302295 | Trial eligibility (AACT) |
| NCT06597994 | Trial eligibility (AACT) |
| NCT06908460 | Trial eligibility (AACT) |
| NCT06727877 | Trial eligibility (AACT) |
| NCT04699682 | Trial eligibility (AACT) |
Showing 5 of 27 trial mentions.
Target-disease associations (250)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormal sperm morphology | phenotype | Expression Atlas |
| Alzheimer disease | nervous system disease | crispr screen |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Autosomal dominant polycystic kidney disease | genetic, familial or congenital disease | Literature (Europe PMC) |
| BAP1-related tumor predisposition syndrome | cancer or benign tumor | Mouse knockout (IMPC) |
Showing 5 of 250 associations.
Vendor sourcing (74)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Amber Therapeutics Ltd | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Participant has exited the AURA-2 clinical investigation. * Participant has an implanted Amber UI system. * Consents to participation. | View trial NCT06597994 |
| Amber Therapeutics Ltd | Trial sponsor | Mentioned in trial textTrial free-text mention | AURA | View trial NCT06597994 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1040C>T (p.T347I) alteration is located in exon 11 (coding exon 8) of the AURKA gene. This alteration results from a C to T substitution at nucleotide ... | View ClinVar record SCV003730163.2 |
| Association d' Utilisation du Rein Artificiel SANTE | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * All stage 4 and 5 Chronic Kidney Disease patients that were included in the program from 01/01/2021 to 31/12/2021 in the clinics of AURA SANTE | View trial NCT06219798 |
| Association d' Utilisation du Rein Artificiel SANTE | Trial sponsor | Mentioned in trial textTrial free-text mention | AURA | View trial NCT06219798 |
Showing 5 of 74 sourcing records.
Trial-cited literature (228)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment. | JCO precision oncology | 2025 | 3 |
| Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. | Hepatology (Baltimore, Md.) | 2024 | 88 |
| Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024 | 23 |
| A Real-World Study of Patient Characteristics and Clinical Outcomes in <i>EGFR</i> Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice. | Cancers | 2024 | 18 |
| Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis. | Chinese journal of cancer research = Chung-kuo yen cheng yen chiu | 2024 | 10 |
Showing 5 of 228 papers.
Protein variant mentions (7)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D47A | 1 | 2002 | PMID 11827981 |
| p.F31I | 6 | 2007 to 2019 | PMID 30777875, PMID 30093449, PMID 28155045 |
| p.I57V | 5 | 2008 to 2021 | PMID 34758846, PMID 30777875, PMID 30093449 |
| p.L792X | 1 | 2021 | PMID 34558640 |
| p.P31I | 1 | 2006 | PMID 16080195 |
Showing 5 of 7 variants.
Literature-extracted relations (83)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| ADENOSINE TRIPHOSPHATE | Chemical | associate |
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. | 2016 |
| VORINOSTAT | Chemical | negative_correlate |
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. | 2010 |
| (nab)-paclitaxel | Chemical | positive_correlate |
Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. | 2007 |
| (nab)-paclitaxel | Chemical | associate |
AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. | 2003 |
| Carcinoma, Non-Small-Cell Lung | Disease | associate |
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment. | 2025 |
Showing 5 of 83 relation assertions.
Organizations publishing (270)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 17 | 2011 to 2023 |
| The University of Texas System | Academic | 11 | 2001 to 2024 |
| Mayo Clinic | Hospital | 10 | 2014 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 9 | 2011 to 2020 |
| Harvard Medical School | Academic | 8 | 2009 to 2022 |
Showing 5 of 270 organizations.
Where AURKA appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- urinary system disease
213 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.